Vetter Pharma International GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter Development Service: Filling your clinical development needs

Vetter Development Service supports your drug-development projects, from inception to market launch. Our Chicago facility, along with our existing sites, provides clinical manufacturing from preclinical development through Phase II, with scale-up and transfer to our commercial manufacturing facilities.

Early planning can help save costs: Together, we work with you to develop the appropriate delivery system for your drug, starting in early development. In addition to matching all components to your product’s specifications, we replicate commercial manufacturing processes in our laboratories, which can prevent surprises when your drug reaches market production. Once products reach Phase III, we provide seamless transfer to our large-scale manufacturing facilities in Europe for late-stage and commercial production. Simultaneous activities, coupled with expertise and foresight, reduce time to market. To help prolong your success, Vetter also offers support on product lifecycle management, which ideally begins in the preclinical phase and becomes an integral part of the drug development process.

A leading manufacturer of aseptically prefilled drug-delivery systems, Vetter offers extensive experience with a broad array of substances, including monoclonal antibodies, peptides, interferons and vaccines.

Vetter Development Service provides:

  • Formulation support
  • Process development
  • Clinical trial manufacturing
  • Analytical service
  • Regulatory support

Website: www.vetter-pharma.com
E-mail: info@vetter-pharma.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
FindPharma Custom Search

Click here